



Participant Pictorial Information Sheet Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses PRINCIPLE Trial

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug2022,

EudraCT number: 2020-001209-22

What is the trial about?

	1.	COVID-19 is caused by a new virus that is spreading quickly in many countries.
2	2.	At the moment, we do not have treatments for COVID-19 that we know definitely work to help recovery and prevent hospitalisation.
	3.	The aim of this trial is to test possible treatments for COVID-19. We hope to find treatments that help people recover quicker.

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug 2022, EudraCT number: 2020-001209-22

We are testing treatments that have been used for many years. We will also assess less familiar treatments which might have beneficial effects for the treatment of COVID-19, but which do not yet have a license for use in the UK. There are no reasons to believe the medicines are unsafe. A trial nurse/doctor and/or your GP will review your medical notes and confirm that the medication you may

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug2022, EudraCT number: 2020-001209-22

have been given, is safe for you to take.	

Who can take part?



Anybody aged 18 years or over.

WITH

A **positive test** for COVID-19 which was taken in the last 14 days, AND are unwell with symptoms of COVID-19.
These symptoms may include, a high temperature; a new, continuous cough; loss

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug 2022, EudraCT number: 2020-001209-22

or change to your sense of smell or taste; sore throat; shortness of breath; general feeling of being unwell; muscle pain; diarrhoea, vomiting; fever and cough, and you must have had them in the last 14 days. If you are starting to feel better, this study isn't for you.

What will happen if I take part?



5

If you have a positive test for COVID-19 with symptoms in the past 14 days, please visit our trial website (see end of this leaflet).

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug2022,

EudraCT number: 2020-001209-22

6.	We will ask you to fill in a short form online, to check that you can take part
7.	Your care will not be affected, whether or not you do take part in the trial.
8.	If you are suitable to take part in the trial, you will be asked to fill in a consent form online, and to answer a few questions about yourself and your symptoms.

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug2022,

9.	We will ask you to add details of a 'trial partner'. This is somebody that might be able help you with the study, and who we can also contact for information about how you are getting on.
10.	The information that you give us will be shared with your GP and the study team, so that we can double check that everything is in order for you to take part.
11.	If you can take part, you will be randomly (like tossing a coin) entered into a group:-

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug 2022, EudraCT number: 2020-001209-22



a) Usual care for your symptoms




b) You will receive one of the treatments that we Or are testing, in addition to usual care for your symptoms.

We will provide you with the trial medication and instructions on how to take it.

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v<u>4.0</u>3.<u>10</u>, <u>27 April2808Aug</u>2022,

EudraCT number: 2020-001209-22



Whichever group you are in, we will ask you to answer a few questions each daily in an online diary for up to 28 days, so that we know how you are feeling. If you have been given a less well known treatment, we will contact you within one day of joining the trial to explain what medication you have been given. We may will contact you (by email, text message or telephone call) once a month for up toaftert 3, 6, and 12 months (within 3

months of the

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

12.

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug2022, EudraCT number: 2020-001209-22

	timepoints) after you enrol into the trial to collect information about ongoing symptoms, hospital visits and your wellbeing
13	If you are a woman of child bearing potential or a male with a partner of child bearing potential, you will also be required to use highly effective contraception during your participation in the trial.
	If you are a woman of child bearing potential, you may be required to take a pregnancy test

Pictorial Participant Information Booklet DRAFT v $\underline{4.03.10}$, $\underline{27}$ April $\underline{2808}$ Aug2022,

EudraCT number: 2020-001209-22

	before starting your course of treatment.
14.	If you are unable to answer questions online, or forget to complete the questions, we might give you a phone call or send you a text message reminder.
15.	If you are admitted to hospital, we would ask you, or someone close to you, to let us know.

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug 2022, EudraCT number: 2020-001209-22




If you agree to join the study, we will contact you at 28 days to see whether you are happy for us to arrange to speak with you in more detail about your experience of taking part in the trial. Samples you have given or go on to give for COVID-19 in your standard care may also be used for national surveillance. If this is the case we would like to access the results from any samples (including testing swabs and convalescent blood samples) held in your GP record or by **Public Health England** UK Health

16.

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug2022,

EudraCT number: 2020-001209-22



What will happen to my information?

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v $\underline{4.03.10}$, $\underline{27}$ April $\underline{2808}$ Aug $\underline{2022}$,

EudraCT number: 2020-001209-22

17.	We will use the information you give us to find out which treatments work. We may also look at your general practice and hospital medical records for further information about you and your illness.
18.	Any information that we collect about you will be kept safe. Your name will not go on any reports, presentations or publications.

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April 2808 Aug 2022,

EudraCT number: 2020-001209-22

What are the disadvantages of taking part?



There is a risk of side effects when taking any medicine. If you are taking a trial medication and have any symptoms, you can record them in the daily online diary.

19. A trial doctor will monitor any sideeffects you may experience and contact you or your GP if needed. You will also be able to call the trial nurse/doctor if you experience any sideeffects.

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug2022, EudraCT number: 2020-001209-22

What are the benefits of taking part?



You will be contributing to important research 20. to find effective treatments for COVID-19.



trial so that whilst the trial is ongoing, if we find that one treatment is more effective, more people might receive this treatment. This means that more people in the trial have a chance of receiving the most effective trial treatment.

We have designed the

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug2022,

EudraCT number: 2020-001209-22

Will I be reimbursed for taking part?



22


You will receive a gift voucher for £20 once we receive your completed online symptom diary, as a thank you for taking part.

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v $\underline{4.03.10}$, $\underline{27}$ April $\underline{2808}$ Aug 2022,

EudraCT number: 2020-001209-22

What if I do not want to carry on being part of the trial?



Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v $\underline{4.03.10}$, $\underline{27}$ April $\underline{2808}$ Aug $\underline{2022}$,

EudraCT number: 2020-001209-22

What if there is a problem?



25

If you have a concern about any aspect of this trial at any time, you can contact the trial team or the University of Oxford Research Governance, Ethics & Assurance Clinical Trials and Research Governance (RGEACTRG) office (Contact details below).

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April 2808 Aug 2022,

EudraCT number: 2020-001209-22

Trial contact details



Thank you!

Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Pictorial Participant Information Booklet DRAFT v4.03.10, 27 April2808Aug2022,

EudraCT number: 2020-001209-22